AlphaTON stock soars 200% after pioneering digital asset oncology initiative

Investing.com -- AlphaTON Capital Corp (NASDAQ:ATON) stock skyrocketed 200% after announcing plans to evaluate tokenization of its mesothelioma treatment program, combining blockchain technology with cancer therapeutics.

The Nasdaq-listed company revealed a non-binding letter of intent to explore tokenizing single-indication economics for its TT-4 treatment in mesothelioma. This initiative represents AlphaTON’s strategy to merge its TON ecosystem operations with the clinical-stage pipeline of its wholly owned oncology subsidiary, Cyncado Therapeutics.

Cyncado is preparing for first-patient dosing of TT-4, an oral A2B receptor antagonist, targeted for the first quarter of 2026. The drug has shown promising preclinical results in mesothelioma models, including over 90% tumor growth inhibition when combined with anti-PD1 antibody therapy and 60% complete responses in combination treatments.

"We are witnessing the birth of a new paradigm in biomedical innovation," said Brittany Kaiser, Chief Executive Officer of AlphaTON Capital. "By thoughtfully integrating our digital asset capabilities with Cyncado’s compelling oncology programs, we’re not just exploring novel financing mechanisms, we’re pioneering the future of decentralized science."

The company emphasized that this exploratory initiative is designed to preserve traditional pathways for therapeutic development, including partnerships, licensing, and acquisition opportunities. Any future transaction would require board approval and regulatory clearance.

AlphaTON positions itself as the only Nasdaq-listed company simultaneously operating a strategic TON token treasury while advancing cancer immunotherapy assets, leveraging decentralized science principles to potentially transform how medical research is funded and accelerated.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.